Payment overview · 2025
General Payments
$144.20
9 reported records · 6 companies
Healthcare provider profile · identity verified
Daniel Barbero
Allopathic & Osteopathic Physicians|Internal Medicine · ERIE, PA · NPI 1710986534
Verified facts
What the public records show
CMS Open Payments records show Daniel Barbero received $144.20 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.94 | 31.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.48 | 19.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.60 | 15.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.39 | 12.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.73 | 11.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.06 | 9.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $144.20 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.94 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.97 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.48 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.48 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 162 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
162 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1030 | 307 |
| Lisinopril | Lisinopril | 556 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 509 | 164 |
| Pantoprazole Sodium | Pantoprazole Sodium | 432 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 111 |
| Losartan Potassium | Losartan Potassium | 400 | 121 |
| Gabapentin | Gabapentin | 372 | 86 |
| Metformin Hcl | Metformin Hcl | 326 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 280 | 85 |
| Omeprazole | Omeprazole | 262 | 79 |
| Simvastatin | Simvastatin | 248 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 206 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 63 |
| Potassium Chloride | Potassium Chloride | 189 | 45 |
| Atenolol | Atenolol | 187 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 180 | 52 |
| Furosemide | Furosemide | 177 | 57 |
| Eliquis | Apixaban | 162 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 162 | 40 |
| Lorazepam | Lorazepam | 156 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 41 |
| Sertraline Hcl | Sertraline Hcl | 155 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 51 |
| Mirtazapine | Mirtazapine | 113 | 27 |
| Allopurinol | Allopurinol | 103 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 100 | 16 |
| Warfarin Sodium | Warfarin Sodium | 100 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 33 |
| Tramadol Hcl | Tramadol Hcl | 99 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 23 |
| Carvedilol | Carvedilol | 95 | 28 |
| Trazodone Hcl | Trazodone Hcl | 93 | 33 |
| Bumetanide | Bumetanide | 89 | 19 |
| Famotidine | Famotidine | 89 | 25 |
| Jardiance | Empagliflozin | 88 | 22 |
| Prednisone | Prednisone | 84 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 80 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 27 |
| Metformin Hcl Er | Metformin Hcl | 77 | 25 |
| Spironolactone | Spironolactone | 77 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 23 |
| Glimepiride | Glimepiride | 74 | 19 |
| Buspirone Hcl | Buspirone Hcl | 73 | 19 |
| Meloxicam | Meloxicam | 71 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 20 |
| Montelukast Sodium | Montelukast Sodium | 65 | 21 |
| Alprazolam | Alprazolam | 64 | 15 |
| Ezetimibe | Ezetimibe | 64 | 18 |
| Xarelto | Rivaroxaban | 63 | 16 |
| Finasteride | Finasteride | 61 | 15 |
| Meclizine Hcl | Meclizine Hcl | 59 | 19 |
| Synthroid | Levothyroxine Sodium | 58 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 15 |
| Alendronate Sodium | Alendronate Sodium | 54 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 14 |
| Ozempic | Semaglutide | 50 | 12 |
| Nystatin | Nystatin | 49 | 26 |
| Pregabalin | Pregabalin | 49 | 11 |
| Glipizide Er | Glipizide | 48 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 11 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 42 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 11 |
| Baclofen | Baclofen | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 28 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Celecoxib | Celecoxib | 31 | 14 |
| Mupirocin | Mupirocin | 31 | 25 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Jantoven | Warfarin Sodium | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Epinephrine | Epinephrine | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 20 | 13 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Diazepam | Diazepam | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $144.20 · 9 records | Amgen Inc. | CAPLYTA, ELIQUIS, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, WATCHMAN FLX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error